KuDOS Pharmaceuticals Limited Company Profile

11:09 EDT 21st March 2018 | BioPortfolio

KuDOS Pharmaceuticals is a leader in the discovery and development of novel small molecule drugs that target DNA repair and related systems for the treatment f human diseases, in particular cancer. The company was founded by Professor Stephen Jackson of the Wellcome/Cancer Research UK Institute of the University of Cambridge, UK, an internationally renowned scientist in the field of DNA repair.

The company, including its subsidiary, ChemOvation Ltd currently employs 60 people.

KuDOS Pharmaceuticals has identified a number of naturally occurring DNA repair mechanisms and proteins that are fundamental to the control of cell growth and cell death. Whilst primarily focused on the discovery and development of novel therapeutic agents for use in cancer therapy, DNA repair inhibitors can also be used in the treatment of viral infections, ischaemia and immunosuppression.

Since May 1999, KuDOS Pharmaceuticals has established a strong scientific platform that has resulted in the identification of several new classes of promising drug candidates targeted at DNA repair enzymes for the treatment of cancer. KuDOS’ leading product, PaTrin-2, is planned to enter Phase II clinical trials in melanoma and colorectal cancer by 3-4Q 2002. AQ4N, a hypoxic cell cytotoxin, is currently in Phase I evaluation.

Other products are entering pre-clinical studies with the aim of initiating Phase I clinical trials by 2Q 2003/1Q 2004.

Each of KuDOS’ products is based on a detailed molecular understanding of tumour cells and will enhance efficacy of ionising radiation and major chemotherapy regimen.

Product portfolio:

PaTrin-2: Phase II commencing Q4 2002

AQ4N: Phase I ongoing

DNA-PK/ATM inhibitor: Pre-clinical development commencing Q2/3 2002

PARP inhibitor: Pre-clinical development commencing Q3/4 2002

KuDOS Pharmaceuticals has a range of products for development as cancer treatments and will take these forward to Phase II clinical trials prior to partnering products with major pharmaceutical companies for product approval and commercialisation. Applications for other than cancer treatment will be out-licensed at an earlier stage.


327, Cambridge Science Park, Milton Road,
United Kingdom


Phone: 01223 719719
Fax: 01223 719720

News Articles [537 Associated News Articles listed on BioPortfolio]

Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the developmen...

Research kudos does not need a price tag

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagn...

Innovation Pharmaceuticals Views Brilacidin-OM as Clearly Differentiated Compared to Limited Competition for Preventing Severe Oral Mucositis

BEVERLY, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide shareholders wit...

Screening: Do you follow guidelines or your gut?

The commentary below is meant to invoke meaningful discourse rather than incite an unpleasant argument. Less than a year ago, I heard Ben Stiller doling out kudos to his heroic doctor who diagnosed hi...

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and ...

Salix Pharmaceuticals (SLXP) vs. Its Rivals Head to Head Survey

Salix Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its rivals? We will compare Salix Pharmaceuticals to related...

Critical Contrast: Ironwood Pharmaceuticals

Ironwood Pharmaceuticals and Infinity Pharmaceuticals are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, d...

PubMed Articles [119 Associated PubMed Articles listed on BioPortfolio]

Analysing researchers' outreach efforts and the association with publication metrics: A case study of Kudos.

With the growth of scholarly collaboration networks and social communication platforms, members of the scholarly community are experimenting with their approach to disseminating research outputs, in a...

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Clinical Trials [211 Associated Clinical Trials listed on BioPortfolio]

Kansas University DHA Outcome Study (KUDOS) Follow-Up

This is a continuation study to KUDOS (NCT00266825). The purpose of this study is to follow-up with participants on the original study to determine if the effects of increasing DHA intake...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Companies [1383 Associated Companies listed on BioPortfolio]

KuDOS Pharmaceuticals Ltd

KuDOS Pharmaceuticals Limited holds a leading position in the discovery and development of drugs based upon the science of DNA damage sensing, signalling and repair to address unmet medical needs in c...

KuDOS Pharmaceuticals Limited

KuDOS Pharmaceuticals is a leader in the discovery and development of novel small molecule drugs that target DNA repair and related systems for the treatment f human diseases, in particular cancer. T...

Ranbaxy Pharmaceuticals Inc.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical comp...


J. B. Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing, professionally managed, global pharmaceutical companies manufacturing a wide range of innovative specialty medicines...


The first unit of AARTI group, ALCHEMIE LABORATORIES, commenced commercial production of DIMETHYL SULPHATE (DMS) in the year 1975. Today, AARTI has acquired world-class expertise in the development an...

More Information about "KuDOS Pharmaceuticals Limited" on BioPortfolio

We have published hundreds of KuDOS Pharmaceuticals Limited news stories on BioPortfolio along with dozens of KuDOS Pharmaceuticals Limited Clinical Trials and PubMed Articles about KuDOS Pharmaceuticals Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of KuDOS Pharmaceuticals Limited Companies in our database. You can also find out about relevant KuDOS Pharmaceuticals Limited Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record